Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== Environmental record == As of 2013, UPS has over 104,900 vehicles in operation worldwide including nearly 7,000 alternative fuel vehicles. In May 2008, UPS placed an order for 200 hybrid electric vehicles (adding to the 50 it had at that point) and 300 compressed natural gas (which are 20% more fuel efficient, and add to the 800 it already has) vehicles from Daimler Trucks North America. The company added 200 hybrid electric vehicles to its fleet in 2016. UPS received a "striding" rating of 80 points out of 100 totals on the environmental scorecard by the Climate Counts Group for its efforts to lessen the company's impact on the environment. UPS has also been awarded the Clean Air Excellence Award by the United States Environmental Protection Agency because of the alternative fuel program it has developed. A few years later, the Environmental Protection Agency fined the UPS for not following environmental laws. In October 2009, UPS became the first small-package carrier to offer customers the chance to buy carbon offsets to neutralize the greenhouse gas emissions generated by the transport of their packages. Although initially only available on ups.com and to high-volume shippers, they are now widely available through UPS shipping systems and UPS Ready third-party shipping systems.
AlbuRx, Alburex, Albumeon, Human Albumin Behring, Albuminar 25, human albumin solution (5%, 20% or 25% human albumin solutions) Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate Beriplex P/N, freeze-dried human prothrombin complex concentrate Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate Kybernin P, freeze-dried human antithrombin III concentrate Streptase, freeze-dried streptokinase Wound Healing:
Tetrahydroharmine is a harmala alkaloid found in organisms such as Daphnia pulex and Euglena gracilis. Tetrahydroharmine, a component of ayahuasca with weak SSRI properties, has been associated with increased serotonin uptake sites and variable psychoactive effects, with preferences for higher tetrahydroharmine content reported in some ayahuasca-using churches, potentially due to differences in plant composition and preparation methods.
Sources: en.wikipedia.org
=== Murder of Charmaine West === Rose is believed to have murdered Charmaine shortly before Fred's prison release date of 24 June 1971. She is known to have taken Charmaine, Anne Marie and Heather to visit Fred on 15 June, and it is believed that Charmaine was killed on or very shortly after this date. As well as forensic dentistry confirming that Charmaine had died while Fred was still incarcerated, further testimony from Tracey Giles' mother, Shirley, corroborated the fact that Charmaine had died before Fred's release. In her later testimony at Rose's trial, Shirley stated that her two daughters had been playmates of Charmaine and Anne Marie when her family lived in the upper flat of 25 Midland Road in 1971. Shirley further stated that after her family had vacated the flat in April 1971, she had brought Tracey to visit Charmaine on a day in June, only for Tracey to be told by Rose: "She's gone to live with her mother, and bloody good riddance!" Shirley Giles was adamant that Fred was still in prison on this occasion. As with the Giles family, Rose explained Charmaine's disappearance to others who enquired about her whereabouts by claiming that Fred's first wife, Catherine "Rena" West, had taken her eldest daughter to live with her in Bristol. She contradictorily informed staff at Charmaine's primary school that the child had moved with her mother to London. When Fred was released from prison on 24 June, he allayed Anne Marie's concerns for her sister's whereabouts by claiming Rena had collected Charmaine and returned to her native Scotland.
Although protests against Bukele occurred in 2020 during the COVID-19 pandemic and in 2023 about his re-election campaign and gang crackdown, he has retained high job-approval ratings throughout his presidency. Bukele's approval rating has never gone below 75 percent, and has averaged in the 90s. He is one of the most popular presidents in Salvadoran history, and the Los Angeles Times' Kate Linthicum called him "one of the most popular leaders in the world". The United States Institute of Peace's Mary Speck referred to Bukele as "Latin America's — and possibly the world's — most popular leader". Risa Grais-Targow, a director at the Eurasia Group, described Bukele's approval rating as "sky-high" and "really unprecedented". In addition to Bukele's domestic popularity, he is also very popular among Salvadorans living in the United States and throughout Latin America. Some Latin American state leaders and other politicians have sought to emulate his government policies. In some countries, such as Colombia and Ecuador, opinion polls found Bukele more popular with their residents than domestic politicians. Steven Levitsky, a political scientist and the director of Harvard University's Latin American studies center, wrote that "everybody wants to be a Bukele" and compared his popularity across Latin America to that of former Venezuelan president Hugo Chávez. Some political analysts consider Bukele's popularity a cult of personality.
Trump names himself as the headliner for the "Great American State Fair" semiquincentennial event, organized by Freedom 250, in Washington D.C., after several artists pull out over concerns that the event became politicized by Trump. Martina McBride, Young MC, Bret Michaels, and the Commodores were among the artists who pulled out. A revised lineup includes artists such as Flo Rida, Milli Vanilli, and Vanilla Ice. May 31 – The National Basketball Association announces that the logo for the Larry O'Brien Championship Trophy will be displayed on the basketball courts of Frost Bank Center in San Antonio, Texas, and Madison Square Garden in New York City for the upcoming NBA Finals between the San Antonio Spurs and New York Knicks, making it the first time the logo decal will be placed on the NBA court during the NBA Finals since 2009.
Sources: en.wikipedia.org
Approximately 0.2 to 1% of people have a "weak D" phenotype, meaning that they are positive for the RhD antigen, but exhibit weak or negative reactions with some anti-RhD reagents due to decreased antigen expression or atypical variants of antigen structure. If routine serologic testing for RhD results in a score of 2+ or less, the antiglobulin test can be used to demonstrate the presence of RhD. Weak D testing is also performed on blood donors who initially type as RhD negative. Historically, blood donors with weak D were treated as Rh positive and patients with weak D were treated as Rh negative in order to avoid potential exposure to incompatible blood. Genotyping is increasingly used to determine the molecular basis of weak D phenotypes, as this determines whether or not individuals with weak D can produce antibodies against RhD or sensitize others to the RhD antigen.
Amylopectin has seen a rise of use in biomedical applications due to its physiological factors, ease of availability, and low cost. Specifically, amylopectin has very advantageous biochemical properties due to its prevalence as a natural polysaccharide. This causes a high sense of biocompatibility with cells and molecules within the body. Amylopectin is also able to biodegrade to a high degree due to its high sense of crosslinking with 1,6 glycosidic bonds. The bonds easily broken down by the body can reduce molecular weight, expose certain regions, and interact certain bonds with clinical factors. Various physical, chemical, and enzymatic methods of modification have also been researched for amylopectin. These, generally, allow for enhanced and controllable properties which can be selected for the field of research performed. Amylopectin's main role, clinically, is within its integration in starch. Function and structure of amylopectin is based on its integration with amylose and other bounded molecules. Separating these molecules and isolated amylopectin is quite difficult for researchers to perform.
Earlier VR systems took some time for complete acquisition of all tracking sensor information into usable feedback to the user, but this was at a longer timescale compared to the traditional inputs and the display feedback cycle. Improvements have been made since in sensor technology and the software libraries to register movements, and VR games can also include other methods such as limited prediction of a player's movements, to bring sense feedback to the same timescale as rendering. Both issues combine to the overall factor of synchronization between the feedback loops. If the game takes too long to respond to a player's action, even if more than about 25 milliseconds, it further breaks the sense of immersion. While many of the latency problems are resolved with the VR hardware of the 2010s, VR games still must be programmed with these concerns in mind.
== Mechanism of action == Like all sulfonylureas, glimepiride acts as an insulin secretagogue. It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors. Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.